Surmodics, Inc.

Spiral Therapeutics, Inc.

Forsight Vision4, Inc.

Johns Hopkins University

Forsight Vision6, Inc.

Forsight Vision5, Inc.

Journey1, Inc.

Alcon, Inc.

Long Bridge Medical, Inc.

Eugene De Juan

Mark E Deem

Signe R Erickson

Cary J Reich

Signe Erickson Varner

Yair Alster

Randolph E Campbell

K Angela Macfarlane

Douglas Sutton

Thomas A Silvestrini

Ralph A Chappa

Kathleen Cogan Farinas

Aron B Anderson

Laurie Lawin

Vrad Levering

Byron C Shen

Hugo Peris

Jose D Alejandro

Stephen A Boyd

Darren G Doud

Hanson S Gifford, Iii

Michael Barrett

Robert George

David Sierra

Steven M Chamow

Terry Harrison Shelley

Matthew Clarke

Kevin W Sacherman

Dan Rosenman

Christina Skieller

Aaron Christopher Barnes

David Batten

Guy Oren

Greg Stine

Mike Barrett

Charles Limb

Andrew Ayoob

Barak Azmon

Michael J Cooney

Ayman Naseri

Janelle Chang

Omer Rafaeli

Alexander J Gould

K Angela MacFarlane

Nicole Kahn-Dror

Eric T Lee

Yoni Manor

Nathan Robert Fox Beeley

Jonathan Shahar

Laurie R Lawin

Frank Brodie

Hanson S Gifford Iii

Hanson S Gifford

Signe E Varner

The present disclosure is directed to contact lenses for the correcting a refractive error, particularly astigmatism, and other corneal irregularities. An exemplary lens comprises an inner portion, a peripheral portion, and a juncture therebetween. The inner portion provides optical correction for an eye. The peripheral portion conforms to a corneal surface of the eye. The juncture is a structurally flexible portion of the ophthalmic lens such that deformation of the peripheral portion in response to conforming to an astigmatism or higher order aberration of the corneal surface does not substantially deform the inner portion. When the lens is placed on the eye, the inner portion vaults over the corneal surface to form a lenticular volume. The optical correction is provided by a combination of the inner portion and the lenticular volume.

Astigmatism correcting contact lenses

An accommodating intraocular lens device for treatment of an eye having a lens body; internal support; stabilization system; and force translation arm. The lens body includes an accommodating membrane, an annular element, a static element, and a fixed volume of optical fluid filling a sealed chamber of the lens body. The annular element coupled to the perimeter of the accommodating membrane has a shape deformation membrane configured to undergo displacement relative to the perimeter region. The sealed chamber is formed by inner surfaces of the accommodating membrane, shape deformation membrane, and static element. The force translation arm has a first end operatively coupled to the shape deformation membrane and a free end available and configured to engage a ciliary structure of the eye. The force translation arm is moveable relative to the lens body to cause inward movement of the shape deformation membrane. Related methods, devices, and systems are provided.

Accommodating intraocular lens and methods of implantation

Devices, systems, and methods can be employed to facilitate indirect viewing into cavities such as, but not limited to, the middle ear space. Some embodiments have uses such as, but not limited to, facilitating visualization and procedures in the outer, middle, and/or inner ear in order to diagnose and/or treat disorders including, but not limited to, hearing loss and other ear disorders. In particular implementations, a surgical microscope is used in conjunction with an inverter lens and a distal lens. In some cases, the distal lens transverses a membrane or septum such as, but not limited to, the tympanic membrane. The distal lens can be an assembly combining two or more lenses, in some embodiments. For example, in some cases wide angle lenses, zoom lenses, lenses of other various shapes and/or prisms can be used in the distal lens.

Visualization devices, systems, and methods for otology and other uses

An implantable device for delivering a therapeutic agent to treat an ear of a patient includes a body having a distal end region and a proximal end region. The body defines, at least in part, a reservoir configured to contain the therapeutic agent. The device includes a shaft attached to the distal end region of the body and a lumen extending through the shaft having at least one inlet at a proximal end region in fluid communication with the reservoir and at least one outlet at a distal end region. Upon implantation of the body in a region of the ear, a length of the shaft is sufficient to extend from the body to at least the round window membrane of the ear. The device is configured to deliver the therapeutic agent to the ear from the reservoir via passive diffusion. Related devices and methods are described.

Inner ear drug delivery devices and methods of use

Disclosed is an accommodating intraocular lens device for treatment of an eye including a stabilization haptic () configured to be positioned within a region of an eye and a lens body having a sealed chamber containing a fixed volume of optical fluid. The lens body includes a shape changing membrane () configured to outwardly bow in a region surrounding the optical axis of the eye; a shape deformation membrane configured to undergo displacement relative to the first shape changing membrane; and a static element (). An inner surface of the shape changing membrane, an inner surface of the shape deformation membrane and an inner surface of the static element collectively form the sealed chamber. The lens device also includes a force translation arm () having a first end configured to contact an outer surface of the shape deformation membrane of the lens body and a second end configured to engage a ciliary structure of the eye. The force translation arm is configured to move relative to the lens body upon movement of the ciliary structure.

Accommodating intraocular lens

Methods and apparatus provide treatment with a first therapeutic agent and a second therapeutic agent for an extended time. The first therapeutic agent may comprise a VEGF inhibitor and the second therapeutic agent may comprise an antiinflammatory, such as a non-steroidal anti-inflammatory, for example a cyclooxygenase inhibitor. One or more of the first therapeutic agent or the second therapeutic agent can be injected into the eye, for example injected into a therapeutic device implanted into the eye to release the injected therapeutic agent for an extended time.

Combined drug delivery methods and apparatus

Systems and methods can be employed for trans-tympanic membrane access to the middle ear for delivery of a therapeutic agent, for example, to the round window niche adjacent to the cochlea under direct visualization. The systems and methods can also be used to improve accessibility and visualization for various otological surgical procedures, such as, but not limited to, cholesteatoma removal, tympanic membrane repair and ossicular chain repair.

Systems and methods for treating hearing loss

A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

Posterior segment drug delivery

A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

Ocular insert apparatus and methods

A therapeutic device that can release a therapeutic agent comprising a porous structure coupled to a container comprising a reservoir. The reservoir can comprise a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in a patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.

Small molecule delivery with implantable therapeutic device

A delivery device that allows for the sustained release of an agent, particularly useful for the sustained release of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. The delivery device is minimally invasive, refillable and may be easily fixed to the treatment area. The delivery device includes a hollow body with an inlet port at its proximal end for insertion of the agent, a reservoir for holding the agent and a delivery mechanism for the sustained delivery of the agent from the reservoir to the patient.

Reservoir device for intraocular drug delivery

The invention provides a controlled release bioactive agent delivery device for treatment of an eye that includes a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension, and a polymeric coated composition in contact with a surface of the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent. The first polymer and the second polymer are hydrophobic, and the body member has a length such that, upon placement of the device at an implantation site within a posterior segment of an eye, the device does not enter a central visual field of the eye. The invention also provides methods method of delivering bioactive agent to a posterior region of an eye.

Controlled release bioactive agent delivery device

Growing community of inventors

South San Francisco, CA, United States of America

Eugene De Juan